tetano
Editor, Senior Moderator
Curr Microbiol
. 2024 Aug 8;81(9):301.
doi: 10.1007/s00284-024-03786-7. Clinical and Genomic Perspective of SARS CoV-2 Infection in Liver Disease Patients: A Single-Centre Retrospective Study
Reshu Agarwal[SUP] #[/SUP][SUP] 1 [/SUP], Arjun Bhugra[SUP] #[/SUP][SUP] 1 [/SUP], Pramod Gautam[SUP] #[/SUP][SUP] 2 [/SUP], Varun Suroliya[SUP] 2 [/SUP], Ruchita Chhabra[SUP] 1 [/SUP], Amit Pandey[SUP] 1 [/SUP], Prince Garg[SUP] 2 [/SUP], Pooja Rao[SUP] 2 [/SUP], Rosmy Babu[SUP] 3 [/SUP], Guresh Kumar[SUP] 4 [/SUP], Chhagan Bihari[SUP] 3 [/SUP], Debajyoti Bhattacharyya[SUP] 5 [/SUP], S M Shasthry[SUP] 6 [/SUP], Shiv Kumar Sarin[SUP] 6 [/SUP], Ekta Gupta[SUP] 7 [/SUP]
Affiliations
The limited literature on the clinical course of COVID-19 among patients with underlying liver disease (LD) is available from India. The present study aimed to evaluate the clinical and mutational profile of SARS-CoV-2 among LD cases. This was a retrospective study including admitted LD cases in whom SARS-CoV-2 RT-PCR testing was performed. Complete demographic and clinical details were retrieved from Hospital Information System. Detailed mutational analysis was performed by comparing LD COVID-19 positive study group, i.e. LD-CoV(+) with COVID-19 positive outpatients without any underlying LD as control, i.e. NLD-CoV(+). Out of 232 enrolled LD cases, 137 (59.1%) were LD-CoV(+). LD cases with existing co-morbidities were affected more (P = 0.002) and had 2.29 times (OR 2.29, CI 95%, 1.25-4.29) higher odds of succumbing to COVID-19 (P = 0.006). On multivariate regression analysis, ascites (P = 0.05), severe COVID-19 pneumonia (P = 0.046), and an increased levels of bilirubin (P = 0.005) and alkaline phosphatase (P = 0.003) were found to be associated with adverse outcome in LD-CoV(+).On mutational analysis, we found certain differences between LD- and NLD-CoV(+) infected with Delta [LD- and NLD-CoV (+ /D)] and Omicron [LD- and NLD-CoV(+/O)]. More mutations were shared between LD- and NLD-CoV(+/O) compared to LD- and NLD-CoV(+/D). There were differences in prevalence of indel mutations specific to LD-CoV ( +) for both Delta and Omicron. Moreover, we also reported an interesting genic bias between LD- and NLD-CoV( +) in harbouring deleterious/tolerated mutations. To conclude, LD cases with comorbidities were affected more and had higher odds of mortality due to COVID-19. The definite difference between LD- and NLD-CoV(+) groups with respect to frequency of harboured mutations and an inherent genic bias between them is of noteworthy importance.
. 2024 Aug 8;81(9):301.
doi: 10.1007/s00284-024-03786-7. Clinical and Genomic Perspective of SARS CoV-2 Infection in Liver Disease Patients: A Single-Centre Retrospective Study
Reshu Agarwal[SUP] #[/SUP][SUP] 1 [/SUP], Arjun Bhugra[SUP] #[/SUP][SUP] 1 [/SUP], Pramod Gautam[SUP] #[/SUP][SUP] 2 [/SUP], Varun Suroliya[SUP] 2 [/SUP], Ruchita Chhabra[SUP] 1 [/SUP], Amit Pandey[SUP] 1 [/SUP], Prince Garg[SUP] 2 [/SUP], Pooja Rao[SUP] 2 [/SUP], Rosmy Babu[SUP] 3 [/SUP], Guresh Kumar[SUP] 4 [/SUP], Chhagan Bihari[SUP] 3 [/SUP], Debajyoti Bhattacharyya[SUP] 5 [/SUP], S M Shasthry[SUP] 6 [/SUP], Shiv Kumar Sarin[SUP] 6 [/SUP], Ekta Gupta[SUP] 7 [/SUP]
Affiliations
- PMID: 39115704
- DOI: 10.1007/s00284-024-03786-7
The limited literature on the clinical course of COVID-19 among patients with underlying liver disease (LD) is available from India. The present study aimed to evaluate the clinical and mutational profile of SARS-CoV-2 among LD cases. This was a retrospective study including admitted LD cases in whom SARS-CoV-2 RT-PCR testing was performed. Complete demographic and clinical details were retrieved from Hospital Information System. Detailed mutational analysis was performed by comparing LD COVID-19 positive study group, i.e. LD-CoV(+) with COVID-19 positive outpatients without any underlying LD as control, i.e. NLD-CoV(+). Out of 232 enrolled LD cases, 137 (59.1%) were LD-CoV(+). LD cases with existing co-morbidities were affected more (P = 0.002) and had 2.29 times (OR 2.29, CI 95%, 1.25-4.29) higher odds of succumbing to COVID-19 (P = 0.006). On multivariate regression analysis, ascites (P = 0.05), severe COVID-19 pneumonia (P = 0.046), and an increased levels of bilirubin (P = 0.005) and alkaline phosphatase (P = 0.003) were found to be associated with adverse outcome in LD-CoV(+).On mutational analysis, we found certain differences between LD- and NLD-CoV(+) infected with Delta [LD- and NLD-CoV (+ /D)] and Omicron [LD- and NLD-CoV(+/O)]. More mutations were shared between LD- and NLD-CoV(+/O) compared to LD- and NLD-CoV(+/D). There were differences in prevalence of indel mutations specific to LD-CoV ( +) for both Delta and Omicron. Moreover, we also reported an interesting genic bias between LD- and NLD-CoV( +) in harbouring deleterious/tolerated mutations. To conclude, LD cases with comorbidities were affected more and had higher odds of mortality due to COVID-19. The definite difference between LD- and NLD-CoV(+) groups with respect to frequency of harboured mutations and an inherent genic bias between them is of noteworthy importance.